[quick news] on August 29, 2018, Xi'an Jiaotong University set up the highest single scholarship in domestic universities to promote the cultivation of top innovative talents

Xi'an Jiaotong University has set up the highest single scholarship in domestic universities to promote the cultivation of top-notch innovative talents It is reported that the "Yuejie innovative talents training plan" donated by alumni of Xi'an Jiaotong University has been officially implemented since the beginning of this autumn Recently, "yuejieban" talent selection held an interview The first batch of "Yuejie class" of Xi'an Jiaotong University plans to recruit 50 students, and the selected students can obtain a full scholarship of 420000 yuan at most, and complete four years of university study free of charge Http://news.xjtu.edu.cn/info/1033/98113.htm the first solar IBC battery production line in China has started recently The 200MW n-type IBC battery and component project of solar Xining company of State Power Investment Group has started in Xining This is the first production scale IBC battery and module production line in China, which adopts low-cost double-sided full back electrode technology After completion and operation, the average efficiency of the battery can reach 23%, which is 20.3% higher than the conversion efficiency of conventional single-crystal solar cells It is the silicon crystal battery with the highest mass production efficiency in the world Http://digitalpaper.stdaily.com/http_ / 24 / content_ HTM? Div = - 1 the relocation of the school of chemical engineering of Nanjing University of technology to the new campus of Pukou, Jiangbei It is reported that the relocation of the school of chemical engineering of Nanjing University of technology from the old campus of dingjiaqiao, Gulou District to the new campus of Pukou, Jiangbei is expected to be completed in September It is reported that Jiangbei new area is becoming the main bearing area of Nanjing Chemical Industry and new material industry, and Nantong University has established a good interactive relationship with Jiangbei new area Http:// GBT reached a US $130 million cooperation agreement with Roche Recently, global blood therapeutics (GBT), a clinical stage Biomedical Company based in San Francisco, USA, announced an exclusive global license agreement with Roche for inclacumab (a new type of human P-selectin monoclonal antibody) According to the terms of the agreement, GBT will be responsible for all the development, production and promotion of inclacumab worldwide Roche will receive US $2 million in advance from GBT and may receive up to US $125 million in development and marketing milestone payments In addition, Roche can get a share from the sales of inclacumab Https://endpts.com/once-lauded-for-its-clinical-success-roche-casts-off-cardio-program-inclacumab-for-a-merge-2m-to-global-blood-therapeutics/novartis car-t cell product kymriah two indications were approved on the same day Recently, Novartis, a Swiss pharmaceutical giant, announced that the European Commission (EC) has approved kymriah (tisagenlecleucel Two indications, formerly known as ctl019), were used to treat B-cell precursor acute lymphoblastic leukemia (all), patients under 25 years old who were difficult to treat or had two or more relapses, and adult patients who had two or more previous systemic treatments for relapsed or refractory large B-cell lymphoma (R / R DLBCL) https://